TP53 and rectal cancer: The current meta-analysis suggests that p53 status as an independent predictive factor for neoadjuvant radiation-based therapy outcome in patients with rectal cancer, and gene detection may be a better assay to use in the evaluation of p53 status and sensitivity to neoadjuvant radiation-based therapy.